At the IMSUT, Dr. Nagai prepares registration trials for chimeric antigen receptor T-cell therapy and is responsible for outpatient care as well as supporting translational research, clinical studies and investigator-initiated registration trials. In addition, Dr. Nagai serves as a clinical advisor at the Office of New Drug V (Oncology) and the Companion Diagnostics Working Group, PMDA, where he assists in regulating oncologic drugs and companion diagnostics. Dr. Nagai holds an MD and PhD from the University of Tokyo.